Abstract
The clinical effects of thromboxane synthetase inhibitor and Nizofenone were examined. The subjects were 33 patients on whom clipping of cerebral aneurysm was done within three days of onset of subarachnoid hemorrhage (SAH) and on whom angiography and CT were performed at a stage of acme of vasospasm. They were divided into the thromboxane synthetase inhibitor monotherapy group (7 patients), the Nizofenone monotherapy group (4 patients), the combination therapy group of both drugs (7 patients), and a control group of 15 patients. The effects of thromboxane synthetase inhibitor were measured by the degree of angiographical vasospasm. As for the SAH in Fisher groups 3 and 4, the degree of vasospasm was significantly milder in the thromboxame synthetase inhibitor use group than in the group which did not use this inhibitor (p<0.05). On the other hand, the effects of Nizofenone were measured by the degree of low density on CT. In patients with a mild vasospasm, the Nizofenone-use group showed less tendency to exhibit low density than the group which did not use Nizofenone (p<0.01). Also, the outcome was evaluated with the Glasgw outcome scale (GOS), and the effects of thromboxane synthetase inhibitor and Nizofenone on such outcome were examined. Relating to the SAH in the Fisher groups 1 and 2, the thromboxane synthetase inhibitor and/or Nizofenone therapy groups showed favorable outcome in every case. On the other hand, with respect to the SAH in Fisher groups 3 and 4, no difference was observed in the outcome between the thromboxane synthetase inhibitor and/or Nizofenone therapy groups and the control group.
Thromboxane synthetase inhibitor and Nizofenone seem to have some clinical utility even though there may be a limit to their effect.
